Skip to content
AIOS

Product Expansion Lead at AIOS — Remote, $200k–$400k/yr + 0.15%–0.50% equity

Remote (US hours)Remote · United States
Staff · FullTime · Growth
POSTED 2 NOVVERIFIED 45M AGO
Apply Ask
Role
8 days opentrue age
Posted 2 Nov
Pay
$120k–$210kno pay posted
Market p25–p75
$120k–$210k
United States · n=3520 · 365d to 11 Nov
CompanyAIOS →
16open roles
Opened · 30d
+2
Closed · 30d
−1
10d of snapshots · 30d window
Market
23,266open · Staff Other
Opened · 7d
+1,9608% of open
All other
625,683open
All tracked boards · live 11 Nov · n=23,266

About AIOS

AIOS is building the world’s first full-stack AI doctor.

We’re at $450M ARR, growing from $7M/yr in April 2025. We’re faithfully serving 200k/mo patients via Bolt Pharmacy, our main UK brand. We’ve just launched Bolt Med, our international brand. We’re profitable.

Our strategy exists at the intersection of two strong theses:

The AI doctor that wins will get to escape velocity using GLP-1s, the fastest growing consumer product in history.

The $2T European healthcare market is overlooked by the most talented builders.

Our master plan:

Step 0 → $100M/yr by end of 2025: We went from $10M to $100M in 6 months serving the UK GLP-1 market.

Step 1 → $1B ARR by end of 2026: Since April 2025 we've grown from 3k to 200k UK active GLP-1 patients. We’ll continue this growth curve to hit $1B ARR.

Step 2 → $10B ARR by end of 2028: Blitzscale Europe. We’ll be Europe’s largest GLP-1 provider.

Step 3 → $100B/yr by end of 2030: Get regulatory approval across Europe for our Full Autonomous Prescribing (FAP) system. Win contracts at scale with European payers to mass replace human labor. We’ll be the dominant full-stack AI doctor in Europe.

Step 4 → $1T/yr by end of 2035: With one line of code and zero human time, you can use AIOS to treat any patient globally with any medication.

In so doing, we’ll become the world’s first trillion-dollar healthcare company.

We’re a young, founder-led company. This is still Day 1 and all our work is ahead of us.

You can read more about working with us here: Working at AIOS

Being the Product Expansion Lead at AIOS

We’re building a world-class team.

As Product Expansion Lead at AIOS, your fundamental role is to drive new category growth.

The rest of the org will stay maniacal about their One Thing (global GLP-1 uptake), while your One Thing will be launching and scaling non-GLP-1 products. We’re currently live with 0 non-GLP-1 products, so this is very much a builder role.

If it’s not a GLP-1, you’ll stay the overall DRI in perpetuity: from TOF acquisition through to retention, and everything in-between. You’ll build a lean, killer team under you as the function grows, but to start with it’ll be on you to run the entire motion.

You’ll:

Analyze the market to identify which products to launch

Own the growth strategy: Creative, Performance, Funnel work, organic, and lifecycle

Work across Clinical, Product, and Ops teams to make sure protocols, supply chains, and productization are in place for every new category

Great performance in this role means average order value (AOV), incremental LTV, and cross-sell rate all improve, starting with our UK business. If you really nail the role, you’ll be a leading candidate for future senior growth roles (VP Growth, CGO).

This is a full-time, fully remote role, and you’ll work async in the timezone of your choice — as long as you’re around until midday Pacific Time for calls as needed.

You’ll report directly to me, Richie (our CEO). I’m intense, so you’ll also be intense. You’ll work long days and regularly weekends.

You’ll also work closely with:

Dave Lane (Head of Performance)

Michael McCann (Head of CRO)

Key responsibilities

Analysis: Maintain a deep understanding of the consumer health market, and use false-door tests, surveys, competitor analysis, and customer data to build conviction before committing to a launch.

Launches: Take new categories from 0→1. Own the launch plan end-to-end, coordinating Clinical, Product, Ops, and Growth so products go live quickly and cleanly.

Growth: Build the growth strategy for each vertical, from cold acquisition through retention, and everything in-between. You won’t execute every channel yourself, but you’ll remain overall DRI.

Cross-sell: Deftly weave cross-sells into the existing GLP-1 patient journey without adding CVR%-killing friction.

Economics: Own the unit economics of every vertical. Understand CAC, gross margin, attach rate, cross-sell rate, AOV, retention, payback, and incremental LTV. Rapidly iterate based on the numbers.

Retention: Ensure each vertical has a reason to exist beyond the first transaction. Build the product, lifecycle, and customer journey required to drive repeat usage and long-term customer value.

Source · AIOSFirst seen 2 NovOriginal ↗